Dr Reddys Laboratories Quarterly Results for Trading Insights
In Mar 2026, Dr Reddys Laboratories (DRREDDY) reported revenue ₹7,996 Cr and net profit ₹221 Cr — revenue -11.5% YoY. Also explore Dr Reddys Laboratories stock price data download to track price trends across different timeframes.
DRREDDY Quarterly Results — Revenue, Profit & EPS Highlights
Dr Reddys Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit DRREDDY stock price BSE.
- Revenue of ₹7,996 Cr in Mar 2026 (-12.5% vs Sept 2025, -11.5% vs Mar 2025)
- Net Profit of ₹221 Cr in Mar 2026 (-83.5% vs Sept 2025, -86.1% vs Mar 2025)
- EBITDA of ₹832 Cr in Mar 2026 (-64.1% vs Sept 2025)
- Operating Margin of 5.0% in Mar 2026 (-18.0pp vs Sept 2025)
- Earnings Per Share of ₹2.65 in Mar 2026 (-83.6% vs Sept 2025)
Dr Reddys Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
DRREDDY quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 7,996 | 9,135 | 9,034 | 8,836 | 8,998 | -12.5% | -11.5% |
| Net Profit (₹ Cr) | 221 | 1,337 | 1,587 | 1,410 | 1,190 | - | - |
| EBITDA (₹ Cr) | 832 | 2,317 | 2,503 | 2,437 | 2,132 | - | - |
| EPS (₹) | 2.65 | 16.18 | 19.12 | 17.04 | 14.53 | - | - |
| Operating Margin (%) | 5.0% | 23.0% | 23.0% | 25.0% | 21.0% | - | - |
DRREDDY Share Price Trend — 1-Year Movement Across Quarterly Results
Dr Reddys Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with DRREDDY fair value to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
DRREDDY vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Dr Reddys Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Zydus Life Science
Mar 2026 |
₹107,963.88 Cr | 1085.8 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 85.8 |
All amounts in ₹ Crores